

# Product Sheet



# QVQ

QUALITY IN ANTIBODIES

Yalelaan 1  
3584 CL Utrecht  
The Netherlands  
+31 30 253 3421


www.qvquality.com  
KvK: 30274082  
VAT: 8215.17.168  
NL88 RABO0153194936

## Candidalysin

**Catalogue no.:** Q99c  
**Clone name:** CAL-H1

**Product:** VHH directed against Candidalysin

**Target:** Candidalysin, also known as Ece1-III62-92K, is a 31-amino acid peptide toxin secreted by *Candida albicans*. In a large part of the human population, *Candida albicans* is a commensal fungus, but it can also cause serious mucosal and sometimes life-threatening systemic infections. Proteolytic cleavage of the larger protein Ece1 (extent of cell elongation 1, UniprotKB Q07730), creates the cytolytic pore-forming peptide toxin candidalysin, which is released upon hyphal morphogenesis of the pathogenic yeast, and it can intercalate in and damage host membranes of mostly epithelial cells. This damage triggers a calcium flux and a danger signaling pathway, which activates epithelial immunity.<sup>1-4</sup>



**Source:** Recombinant monoclonal VHH (Llama glama), purified from *S. cerevisiae* using affinity chromatography. Immunization with yeast and filamentous whole cells of *Candida albicans* and phage-display selection on immobilized candidalysin peptide.<sup>5</sup>

**Specificity:** Candidalysin peptide from *Candida albicans*. Can neutralize candidalysin.<sup>5</sup>





**Formulation:** 0.2 µm filtered solution in PBS.

**Mol. Weight:** 15.2 kDa  
**Ext. Coeff. (ε):** 31650  
**A<sub>280</sub> at 1g/L:** 2.1

**Storage:** Shipped on blue ice. Store at 4 °C or -20 °C (aliquots). Addition of 0.02% sodiumazide is optional.

**Applications:** ELISA, Candidalysin neutralization

### Examples:



Binding of Q99 and Q100 to recombinant ECE1 peptide in ELISA. Immunofluorescence microscopy image showing binding of Q99 or Q100 to a tip of a candida albicans hypha upon infection in endothelial cells (arrows, second image) or candidalysin-treated endothelial cells (right two images).

### References:

- 1 Richardson et al., (2018) mBio, 9(1):e02178-17
- 2 Brown et al., (2012) Science Translational Medicine, 4, 165rv113
- 3 Moyes et al., (2016) Nature, 532(7597):64-8
- 4 Mogavero et al., (2021) Cell Microbiol, 23(10):e13378
- 5 WQ2020130838A2